Polidocanol versus hypertonic glucose for sclerotherapy treatment of reticular veins of the lower limbs: study protocol for a randomized controlled trial

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorBertanha, Matheus
dc.creatorSobreira, Marcone Lima
dc.creatorLúcio Filho, Carlos Eduardo Pinheiro
dc.creatorMariúba, Jamil Victor de Oliveira
dc.creatorPimenta, Rafael Elias Farres
dc.creatorJaldin, Rodrigo Gibin
dc.creatorMoroz, Andrei
dc.creatorMoura, Regina
dc.creatorRollo, Hamilton Almeida
dc.creatorYoshida, Winston Bonetti
dc.date2015-12-07T15:30:30Z
dc.date2016-10-25T21:22:25Z
dc.date2015-12-07T15:30:30Z
dc.date2016-10-25T21:22:25Z
dc.date2014
dc.date.accessioned2017-04-06T09:26:22Z
dc.date.available2017-04-06T09:26:22Z
dc.identifierTrials, v. 15, n. 497, p. 1-6, 2014.
dc.identifier1745-6215
dc.identifierhttp://hdl.handle.net/11449/130968
dc.identifierhttp://acervodigital.unesp.br/handle/11449/130968
dc.identifier10.1186/1745-6215-15-497
dc.identifierPMC4301449.pdf
dc.identifier25527165
dc.identifierPMC4301449
dc.identifierhttp://dx.doi.org/10.1186/1745-6215-15-497
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/941508
dc.descriptionThe prevalence of chronic venous disease is high and occurs more frequently in females. According to the clinical, etiological, anatomical, and pathological classification (CEAP) definition, the reticular veins are included in the C1 class and are mainly associated with aesthetic complaints. Several invasive techniques are used for treatment, including mini phlebectomy, laser ablation, and radiofrequency ablation. However, a wide range of sclerosing agents may serve as minimally invasive alternatives, promoting chemical sclerosis of the vein wall. Although this technique is routinely performed around the world, there is no consensus on the most efficacious and safe chemical agent to be used. Inclusion criteria are women between 18 and 69 years old with at least 10 cm long reticular veins in the lower limbs, on the outer side of the leg/thigh. Patients with CEAP 2 to 6, or with allergies, pregnancy, performing breastfeeding, or with any dermatologic or clinical problems will be excluded. Patients with venous ultrasound mapping showing involvement of saphenous trunks and/or a deep venous system will also be excluded. Patients will be randomized into two groups, one receiving 75% pure glucose and the other group receiving 0.2% polidocanol diluted in 70% glucose. Just one limb and one session per patient will be performed. The sclerosing agent volume will not exceed 5 mL. Clinical follow-up will include visits on days 7 and 60, always with photographic documentation. This project aims to enroll 96 patients and subject them to a double-blind treatment after the randomization process. The design is intended to evaluate efficacy through a primary end point and safety through a secondary end point. Forty-eight patients have currently been enrolled. Preliminary results for these patients showed that 25 received treatment, 2 were excluded, and 22 returned after 7 days and showed no greater adverse events. To date, establishing efficacy criteria has not been possible, and no patients have reached the 60-day return point. These data may help doctors choose the best chemical agent for the treatment of reticular veins. ClinicalTrials.gov Identifier: NCT02054325, 3/02/2014.
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.languageeng
dc.relationTrials
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectGlucose solution
dc.subjectHypertonic
dc.subjectIerosing solutions
dc.subjectSclerotherapy
dc.subjectTelangiectasis
dc.subjectVaricose veins
dc.subjectVeins
dc.titlePolidocanol versus hypertonic glucose for sclerotherapy treatment of reticular veins of the lower limbs: study protocol for a randomized controlled trial
dc.typeOtro


Este ítem pertenece a la siguiente institución